Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells
expressing tumour-associated antigens to induce tumour cell killing. This inherently relies …

Ponatinib is a third‐generation BCR:: ABL1 tyrosine kinase inhibitor (TKI) with high potency
against Philadelphia chromosome (Ph)‐positive leukemias, including T315I‐mutated …

Introduction Efficacy of ponatinib-based treatment for patients with Philadelphia
chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has not been compared to …

The introduction of immunotherapy with monoclonal antibodies (mAbs) is a major step
forward for adults and children with B-lineage acute lymphoblastic leukaemia (ALL) and will …

Objectives We recently performed a single‐arm phase II trial of DA‐EPOCH in adults with
acute lymphoblastic leukemia (ALL). We sought to compare these results to those with …

Before the advent of tyrosine kinase inhibitors (TKI) the outcome of Philadelphia
chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) was dismal. The TKI …

Simple Summary Acute lymphoblastic leukemia is a malignant disease which is commonly
treated with various chemotherapeutic drugs. Novel therapeutic options are gaining interest …

Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-
cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional …

With the close of 2023, we wanted to take stock of the seventh year for Blood Advances. It
has been another superb year for the journal, receiving a large number of submissions …

Philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) is the most
common cytogenetic abnormality of B-ALL in adults and is associated with poor prognosis …